Log In
Print
BCIQ
Print
Print this Print this
 

Rixubis (BAX 326)

  Manage Alerts
Collapse Summary General Information
Company Baxter International Inc.
DescriptionRecombinant Factor IX (rFIX) protein
Molecular Target Factor IX
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationHemophilia
Indication DetailsTreat and prevent bleeding in patients over 12 years old with hemophilia B; Treat and prevent bleeding in patients over 16 years old with hemophilia B; Treatment and prophylaxis of bleeding in hemophilia B patients; Treatment and prophylaxis of bleeding in hemophilia B pediatric patients
Regulatory Designation

U.S. - Orphan Drug (Treat and prevent bleeding in patients over 12 years old with hemophilia B);
EU - Standard Review (Treatment and prophylaxis of bleeding in hemophilia B patients)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today